Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PT Diagnos Laboratorium Utama Tbk is a leading healthcare diagnostics company in Indonesia, specializing in laboratory testing services across a wide range of medical fields. Its competitive position is strengthened by a robust network of over 300 laboratories nationwide, enabling it to capture significant market share in the growing diagnostics sector.
The company generates revenue primarily through laboratory testing services, leveraging its extensive network and advanced technology to provide accurate and timely results. Its competitive advantages include a strong brand reputation, strategic partnerships with hospitals, and a focus on innovation in diagnostic technologies.
Growth in healthcare spending in Indonesia, driven by rising incomes and an expanding middle class
Expansion of laboratory services and new testing capabilities
Regulatory changes impacting healthcare and diagnostics sector
Partnerships with hospitals and healthcare providers to increase service reach
Technological disruption from emerging diagnostic technologies that could render current services obsolete
Regulatory changes that could impose stricter compliance requirements or affect pricing structures
Increasing competition from both local and international diagnostic companies entering the Indonesian market
Potential for price wars as new entrants seek to gain market share
Liquidity risk due to significant capital expenditures, which could strain cash flow if not managed properly
Potential pension obligations if the company expands its workforce significantly
moderate - the company's performance is somewhat linked to GDP growth and consumer spending, as healthcare expenditures tend to rise in stronger economic conditions.
Interest rates affect the company's financing costs for capital expenditures, but the impact on demand is limited as healthcare services are often essential regardless of economic conditions.
minimal - the company has a manageable debt-to-equity ratio of 0.39, indicating limited reliance on credit.
growth - the company is positioned to benefit from increasing healthcare demand and technological advancements in diagnostics.
moderate - the stock has shown significant returns but also volatility, particularly influenced by market sentiment and regulatory changes.
